However, despite the functional decline, PD1+CD28− T cells showed residual functional fitness at the tumor site, as revealed by the slight but significant advantage over PD1+CD28+ T cells in terms of GrzB production (Fig. 3G). The gene discussed is CD28; the disease is neoplasm.